- Eculizumab is currently licensed for use in two other diseases caused by abnormal complement activation – Atypical Haemolytic Uraemic Syndrome (aHUS) and Paroxysmal Nocturnal Haemoglobinuria (PNH).
- Unlike in aHUS and PNH, Eculizumab is not licensed for C3G. However, there are some reports of the successful use of Eculizumab in certain cases of C3G.
- In February 2017 NHS England agreed to fund the use of Eculizumab for treatment of recurrence of C3G in the kidney transplant in England.
- NHS England have made it very clear that Eculizumab can only be funded if a number of criteria have been met.
- Your local physician will need to contact the NRCTC if they feel you might benefit from Eculizumab.
- The full guidance can be read below
- It should be noted that if Eculizumab is funded for use, it would be for 4 months only.